Category - Developments

An investigator-led clinical trial has successfully treated its first patient in a study of BioTime’s (NYSE MKT: BTX) Premvia as a carrier for stromal vascular fraction cells (SVF) for the treatment of age-related...

Titan Pharmaceuticals (NASDAQ:TTNP) has treated the first patient in a Phase 1/2 trial of its ropinirole implant intended for the treatment of signs and symptoms of idiopathic Parkinson’s disease (PD). Ropinirole...

Microbix Biosystems (TSX:MBX) announced the withdrawal of legal claims, alleging patent infringement, that were filed in Canadian Federal Court against Microbix by ZeptoMetrix in October 2016. The allegations by...

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) completed the clinical trial component, or Stage 3, of its Hodgkin’s lymphoma (HL) test, known as Telo-HL, and has submitted the data to its statistics consulting partner...

Ortho Regenerative Technologies will begin trading today on the Canadian Securities Exchange under the stock symbol, ORTH. Ortho RTi is an emerging orthopedic and sports medicine technology company with a focus on novel...

Researchers in Australia and the U.S. say they have created a highly elastic surgical glue that can quickly seal even the toughest wounds, without staples or stitches. In a paper published this week in Science...

Theratechnologies (TSX:TH) presented positive 48-week efficacy and safety results at the IDWeek 2017 conference in San Diego for ibalizumab in patients infected with multidrug resistant HIV-1, who completed the 24-week...

Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and...

Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use...

Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively. Arcturus’ technology...